Back to Journals » Drug, Healthcare and Patient Safety » Volume 3

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis

Authors Lewiecki EM

Published 1 December 2011 Volume 2011:3 Pages 79—91

DOI https://doi.org/10.2147/DHPS.S7727

Review by Single-blind

Peer reviewer comments 2

E Michael Lewiecki
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA

Abstract: Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal regulator of osteoclastic bone resorption. Postmenopausal osteoporosis (PMO) is a systemic skeletal disease associated with high levels of RANKL, resulting in a high rate of bone remodeling and an imbalance of bone resorption over bone formation. By inhibiting RANKL in women with PMO, denosumab reduces the rate of bone remodeling, thereby increasing bone mineral density, improving bone strength, and reducing the risk of fractures. In clinical trials of women with osteoporosis and low bone mineral density, denosumab has been well tolerated, with overall rates of adverse events and serious adverse events in women treated with denosumab similar to those receiving placebo. In the largest clinical trial of denosumab for the treatment of women with PMO, there was a significantly greater incidence of cellulitis reported as a serious adverse event, with no difference in the overall incidence of cellulitis, and a significantly lower incidence of the serious adverse event of concussions with denosumab compared with placebo. The evidence supports a favorable balance of benefits versus risks of denosumab for the treatment of PMO. Assessments of the long-term safety of denosumab are ongoing. Denosumab 60 mg subcutaneously every 6 months is an approved treatment for women with PMO who are at high risk for fracture.

Keywords: denosumab, osteoporosis, safety, risk, benefit, FDA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Readers of this article also read:

Adverse drug reactions in older patients: an Italian observational prospective hospital study

Conforti A, Costantini D, Zanetti F, Moretti U, Grezzana M, Leone R

Drug, Healthcare and Patient Safety 2012, 4:75-80

Published Date: 17 July 2012

An exploratory study on medications in Qatar homes

Kheir N, El Hajj MS, Wilbur K, Kaissi RML, Yousif A

Drug, Healthcare and Patient Safety 2011, 3:99-106

Published Date: 20 December 2011

Safety and tolerability of antipsychotics: focus on amisulpride

Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira

Drug, Healthcare and Patient Safety 2010, 2:205-211

Published Date: 1 October 2010

Antidepressant-associated sexual dysfunction: impact, effects, and treatment

Agnes Higgins, Michael Nash, Aileen M Lynch

Drug, Healthcare and Patient Safety 2010, 2:141-150

Published Date: 9 September 2010

New developments in the treatment of optic neuritis

Thomas M Jenkins, Ahmed T Toosy

Eye and Brain 2010, 2:83-94

Published Date: 18 June 2010

Etanercept in psoriasis: the evidence of its therapeutic impact

Andrew Thomson

Core Evidence 2007, 2:0-0

Published Date: 15 March 2007